文献速递免疫规划卫生政策与健康促进

荷兰有医学风险条件儿童接种灭活流感疫苗的成本效果

Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.
PubMed 文献 · Vaccine · 2020-02-28

在荷兰,对有医学风险条件的儿童每年接种灭活流感疫苗(IIV)虽被推荐,但若IIV仅减少流感相关住院和死亡、对非严重结局无实质影响,则每1000名儿童可预防1.59例住院和0.02例死亡,增量成本效果比为每质量调整生命年(QALY)50,297欧元,仅5%概率具成本效果。

要点

  • 假设IIV仅减少严重结局时,每1000名有医学风险条件儿童可预防1.59例住院和0.02例死亡。
  • 增量成本为每1000名儿童21,564欧元,QALY增益0.43,ICER为50,297欧元/QALY。
  • 在基础假设下,免疫接种具有成本效果的概率为5%。

核心结论

  • 若IIV仅减少严重疾病结局(如当前证据所示),对有医学风险条件儿童每年接种不太可能具有成本效果。
  • 结果应谨慎解读,因成本效果在很大程度上取决于致命性流感的发病率和QALY损失,而相关证据稀缺。

研究设计与样本

  • 研究构建健康经济决策树模型,比较每年接种IIV与不接种的健康效果和成本。
  • 模型输入基于作者关于流感相关初级保健就诊的研究及其他文献。
  • 以每获得一个QALY的成本低于20,000欧元视为具有成本效果。
  • 进行概率敏感性分析评估结果稳健性,并做单因素敏感性分析和情景分析评估个体参数的影响。

主要发现

  • 每年接种IIV平均每1000名有医学风险条件儿童预防1.59例流感相关住院和0.02例死亡。
  • 每1000名儿童预期获得0.43个QALY,增量成本为21,564欧元。
  • 与不接种相比,增量成本效果比(ICER)为50,297欧元/QALY。
  • 在基础假设下,免疫接种具有成本效果的概率为5%。
  • 结果受疫苗针对致命性流感的效力、死亡导致的QALY损失和死亡率影响最大。

关键数值与推荐

  • 成本效果阈值:每获得一个QALY的成本低于20,000欧元。
  • 每1000名有医学风险条件儿童:预防1.59例住院和0.02例死亡,QALY增益0.43,增量成本21,564欧元。
  • ICER为50,297欧元/QALY。
  • 基础假设下具有成本效果的概率为5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 结果应谨慎解读,因成本效果在很大程度上取决于致命性流感的发病率和QALY损失,而相关证据稀缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In many countries, annual immunization with inactivated influenza vaccine (IIV) is recommended for children with medical risk conditions. Prior cost-effectiveness analyses found such immunization to be cost saving, but assumed effectiveness against non-severe influenza outcomes and a higher effectiveness against severe influenza outcomes than recent studies would suggest. However, recent vaccine studies do not indicate any reduction in community or outpatient disease episodes in IIV immunized individuals. We therefore evaluated cost-effectiveness of IIV immunization in children with medical risk conditions in the Netherlands, assuming that IIV reduces influenza-related hospitalization and death, but has no meaningful impact on non-severe health outcomes. METHODS: A health economic decision tree model was developed to evaluate health effects and costs of annual IIV immunization versus no immunization. Model inputs were based on our study on influenza-related primary care visits and other literature. Immunization was considered cost effective if associated costs were less than €20,000 per quality-adjusted life year (QALY) gained. Probabilistic sensitivity analyses were performed to assess robustness of results, and one-way sensitivity analyses and scenario analyses were done to assess the influence of individual parameters. RESULTS: Annual IIV prevents an average of 1.59 influenza-related hospitalizations and 0.02 deaths per 1,000 children with medical risk conditions. This results in an expected QALY gain of 0.43 at incremental costs of €21,564 per 1,000 children, corresponding to an incremental cost-effectiveness ratio (ICER) of €50,297/QALY compared to no immunization. Under base case assumptions, immunization had a 5% probability of being cost effective. Results were most influenced by vaccine efficacy against fatal influenza, QALY loss due to death, and mortality rate. CONCLUSIONS: If IIV only reduces severe disease outcomes, as current evidence suggests, annual immunization of medical risk children is unlikely to be cost effective. Results should however be interpreted with caution as cost-effectiveness is largely dependent on incidence and QALY losses for fatal influenza, for which evidence is scarce.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Naber SK, Bruijning-Verhagen PCJL, de Hoog MLA, et al. Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands. Vaccine. 2020. PMID: 32115297. doi:10.1016/j.vaccine.2020.01.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。